Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Hensler, Michal ^a   Vančurová, Irena ^a,b   Becht, Etienne ^c   Palata, Ondřej ^a   Strnad, Pavel ^b   Tesařová, Petra ^d   Čabiňaková, Michaela ^d   Švec, David ^e,f   Kubista, Mikael ^e,f   Bartůňková, Jiřina ^a,b   Špíšek, Radek ^a,b   Sojka, Luděk ^a,b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d CHARLES UNIVERSITY   (Czech Republic)

^e TATAA Biocenter   (Sweden)

^f INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

Breast cancer; Circulating tumor cells; gene expression profiling; peripheral blood mononuclear cells; prognostic

Indexed keywords

CATHEPSIN D; CD24 ANTIGEN; COMPLEMENTARY DNA; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; HERMES ANTIGEN; HISTONE DEACETYLASE 2; HISTONE H2AZ; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN P53; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DOWN REGULATION; ENRICHMENT CULTURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLEX POLYMERASE CHAIN REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84962821302     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1102827     Document Type: Article

References (54)

1. B.Weigelt, J.L.Peterse, L.J.van 't Veer. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670
2. L.R.Bernstein, L.A.Liotta. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 1994; 6:106-13; PMID:7515692; http://dx.doi.org/10.1097/00001622-199401000-00015
3. S.M.Frisch, R.A.Screaton. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13:555-62; PMID:11544023; http://dx.doi.org/10.1016/S0955-0674(00)00251-9
4. -xL expression levels. J Biol Chem 2006; 281:17758-67; PMID:16632475; http://dx.doi.org/10.1074/jbc.M601812200
5. D.Ravid, S.Maor, H.Werner, M.Liscovitch. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005; 24:1338-47; PMID:15592498; http://dx.doi.org/10.1038/sj.onc.1208337
6. M.Mego, S.A.Mani, M.Cristofanilli. Molecular mechanisms of metastasis in breast cancer–clinical applications. Nat Rev Clin Oncol 2010; 7:693-701; PMID:20956980; http://dx.doi.org/10.1038/nrclinonc.2010.171
7. S.Lamouille, J.Xu, R.Derynck. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758
8. M.S.Wicha, D.F.Hayes. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29:1508-11; PMID:21422428; http://dx.doi.org/10.1200/JCO.2010.34.0026
9. S.Braun, B.Naume. Circulating and disseminated tumor cells. J Clin Oncol 2005; 23:1623-6; PMID:15755968; http://dx.doi.org/10.1200/JCO.2005.10.073
10. A.A.Ross, B.W.Cooper, H.M.Lazarus, W.Mackay, T.J.Moss, N.Ciobanu, M.S.Tallman, M.J.Kennedy, N.E.Davidson, D.Sweet et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:2605-10; PMID:8219214.
11. M.Cristofanilli, G.T.Budd, M.J.Ellis, A.Stopeck, J.Matera, M.C.Miller, J.M.Reuben, G.V.Doyle, W.J.Allard, L.W.Terstappen et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-91; PMID:15317891; http://dx.doi.org/10.1056/NEJMoa040766
12. E.Andreopoulou, L.Y.Yang, K.M.Rangel, J.M.Reuben, L.Hsu, S.Krishnamurthy, V.Valero, H.A.Fritsche, M.Cristofanilli. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 2012; 130:1590-7; PMID:21469140; http://dx.doi.org/10.1002/ijc.26111
13. M.Pestrin, S.Bessi, F.Galardi, M.Truglia, A.Biggeri, C.Biagioni, S.Cappadona, L.Biganzoli, A.Giannini, A.Di Leo. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118:523-30; PMID:19597704; http://dx.doi.org/10.1007/s10549-009-0461-7
14. B.Aktas, V.Muller, M.Tewes, J.Zeitz, S.Kasimir-Bauer, C.R.Loehberg, B.Rack, A.Schneeweiss, T.Fehm. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356-60; PMID:21605893; http://dx.doi.org/10.1016/j.ygyno.2011.04.039
15. M.Banys, N.Krawczyk, S.Becker, J.Jakubowska, A.Staebler, D.Wallwiener, T.Fehm, R.Rothmund. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012; 132:121-9; PMID:21562707; http://dx.doi.org/10.1007/s10549-011-1569-0
16. T.Fehm, O.Hoffmann, B.Aktas, S.Becker, E.F.Solomayer, D.Wallwiener, R.Kimmig, S.Kasimir-Bauer. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11:R59; PMID:19664291; http://dx.doi.org/10.1186/bcr2349
17. A.M.Sieuwerts, J.Kraan, J.Bolt-de Vries, P.van der Spoel, B.Mostert, J.W.Martens, J.W.Gratama, S.Sleijfer, J.A.Foekens. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009; 118:455-68; PMID:19115104; http://dx.doi.org/10.1007/s10549-008-0290-0
18. E.Obermayr, F.Sanchez-Cabo, M.K.Tea, C.F.Singer, M.Krainer, M.B.Fischer, J.Sehouli, A.Reinthaller, R.Horvat, G.Heinze et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010; 10:666; PMID:21129172; http://dx.doi.org/10.1186/1471-2407-10-666
19. M.Lauss, A.Kriegner, K.Vierlinger, I.Visne, A.Yildiz, E.Dilaveroglu, C.Noehammer. Consensus genes of the literature to predict breast cancer recurrence. Breast Cancer Res Treat 2008; 110:235-44; PMID:17899371; http://dx.doi.org/10.1007/s10549-007-9716-3
20. P.A.Andreasen, L.Kjoller, L.Christensen, M.J.Duffy. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72:1-22; PMID:9212216; http://dx.doi.org/10.1002/(SICI)1097-0215(19970703)72:1%3c1::AID-IJC1%3e3.0.CO;2-Z
21. J.H.de Witte, J.A.Foekens, N.Brunner, J.J.Heuvel, T.van Tienoven, M.P.Look, J.G.Klijn, A.Geurts-Moespot, N.Grebenchtchikov, T.Benraad et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001; 85:85-92; PMID:11437407; http://dx.doi.org/10.1054/bjoc.2001.1867
22. Z.Ma, D.J.Webb, M.Jo, S.L.Gonias. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001; 114:3387-96; PMID:11591826
23. R.A.Alexander, G.W.Prager, J.Mihaly-Bison, P.Uhrin, S.Sunzenauer, B.R.Binder, G.J.Schutz, M.Freissmuth, J.M.Breuss. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012; 94:125-35; PMID:22287577; http://dx.doi.org/10.1093/cvr/cvs017
24. A.Xue, C.J.Scarlett, C.J.Jackson, B.J.Allen, R.C.Smith. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008; 36:160-7; PMID:18376307; http://dx.doi.org/10.1097/MPA.0b013e31815750f0
25. S.M.Pulukuri, B.Gorantla, J.S.Rao. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 2007; 282:35594-603; PMID:17923479; http://dx.doi.org/10.1074/jbc.M705867200
26. S.M.Thorpe, H.Rochefort, M.Garcia, G.Freiss, I.J.Christensen, S.Khalaf, F.Paolucci, B.Pau, B.B.Rasmussen, C.Rose. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49:6008-14; PMID:2790815
27. M.Glondu, E.Liaudet-Coopman, D.Derocq, N.Platet, H.Rochefort, M.Garcia. Downregulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002; 21:5127-34; PMID:12140763; http://dx.doi.org/10.1038/sj.onc.1205657
28. D.J.Hicklin, L.M.Ellis. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27; PMID:15585754; http://dx.doi.org/10.1200/JCO.2005.06.081
29. A.D.Yang, E.R.Camp, F.Fan, L.Shen, M.J.Gray, W.Liu, R.Somcio, T.W.Bauer, Y.Wu, D.J.Hicklin et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006; 66:46-51; PMID:16397214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3086
30. N.Dhillon, M.Oki, S.J.Szyjka, O.M.Aparicio, R.T.Kamakaka. H2A.Z functions to regulate progression through the cell cycle. Mol Cell Biol 2006; 26:489-501; PMID:16382141; http://dx.doi.org/10.1128/MCB.26.2.489-501.2006
31. S.Hua, C.B.Kallen, R.Dhar, M.T.Baquero, C.E.Mason, B.A.Russell, P.K.Shah, J.Liu, A.Khramtsov, M.S.Tretiakova et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008; 4:188; PMID:18414489; http://dx.doi.org/10.1038/msb.2008.25
32. K.M.Schweitzer, A.M.Drager, P.van der Valk, S.F.Thijsen, A.Zevenbergen, A.P.Theijsmeijer, C.E.van der Schoot, M.M.Langenhuijsen. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996; 148:165-75; PMID:8546203
33. A.J.Wagers, J.B.Lowe, G.S.Kansas. An important role for the α 1,3 fucosyltransferase, FucT-VII, in leukocyte adhesion to E-selectin. Blood 1996; 88:2125-32; PMID:8822932
34. J.E.Draffin, S.McFarlane, A.Hill, P.G.Johnston, D.J.Waugh. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004; 64:5702-11; PMID:15313910; http://dx.doi.org/10.1158/0008-5472.CAN-04-0389
35. E.Olsson, G.Honeth, P.O.Bendahl, L.H.Saal, S.Gruvberger-Saal, M.Ringner, J.Vallon-Christersson, G.Jonsson, K.Holm, K.Lovgren et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011; 11:418; PMID:21957977; http://dx.doi.org/10.1186/1471-2407-11-418
36. P.A.Theodoropoulos, H.Polioudaki, S.Agelaki, G.Kallergi, Z.Saridaki, D.Mavroudis, V.Georgoulias. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288:99-106; PMID:19619935; http://dx.doi.org/10.1016/j.canlet.2009.06.027
37. D.R.Calnan, A.Brunet. The FoxO code. Oncogene 2008; 27:2276-88; PMID:18391970; http://dx.doi.org/10.1038/onc.2008.21
38. R.J.Shaw, L.C.Cantley. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30; PMID:16724053; http://dx.doi.org/10.1038/nature04869
39. G.Singh, A.M.Chan. Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets 2011; 11:536-47; PMID:21486223; http://dx.doi.org/10.2174/156800911795655930
40. Y.Zhao, Y.Wang, W.G.Zhu. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol 2011; 3:276-82; PMID:21669942; http://dx.doi.org/10.1093/jmcb/mjr013
41. R.Califano, L.Landi, F.Cappuzzo. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012; 72 Suppl 1:28-36; PMID:22712795; http://dx.doi.org/10.2165/1163012-S0-000000000-00000
42. D.Bonneau, M.Longy. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109-22; PMID:10923032; http://dx.doi.org/10.1002/1098-1004(200008)16:2%3c109::AID-HUMU3%3e3.0.CO;2-0
43. H.Farmer, N.McCabe, C.J.Lord, A.N.Tutt, D.A.Johnson, T.B.Richardson, M.Santarosa, K.J.Dillon, I.Hickson, C.Knights et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
44. H.E.Bryant, N.Schultz, H.D.Thomas, K.M.Parker, D.Flower, E.Lopez, S.Kyle, M.Meuth, N.J.Curtin, T.Helleday. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
45. R.Katso, K.Okkenhaug, K.Ahmadi, S.White, J.Timms, M.D.Waterfield. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-75; PMID:11687500; http://dx.doi.org/10.1146/annurev.cellbio.17.1.615
46. M.Osaki, M.Oshimura, H.Ito. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9:667-76; PMID:15505410; http://dx.doi.org/10.1023/B:APPT.0000045801.15585.dd
47. S.L.Deming, S.J.Nass, R.B.Dickson, B.J.Trock. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83:1688-95; PMID:11104567; http://dx.doi.org/10.1054/bjoc.2000.1522
48. R.Wang, C.P.Dillon, L.Z.Shi, S.Milasta, R.Carter, D.Finkelstein, L.L.McCormick, P.Fitzgerald, H.Chi, J.Munger et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011; 35:871-82; PMID:22195744; http://dx.doi.org/10.1016/j.immuni.2011.09.021
49. G.M.Delgoffe, T.P.Kole, Y.Zheng, P.E.Zarek, K.L.Matthews, B.Xiao, P.F.Worley, S.C.Kozma, J.D.Powell. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-44; PMID:19538929; http://dx.doi.org/10.1016/j.immuni.2009.04.014
50. S.K.Watkins, A.A.Hurwitz. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
51. B.F.Johnson, T.M.Clay, A.C.Hobeika, H.K.Lyerly, M.A.Morse. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007; 7:449-60; PMID:17373897; http://dx.doi.org/10.1517/14712598.7.4.449
52. P.Zhang, T.Maruyama, J.E.Konkel, B.Abbatiello, B.Zamarron, Z.Q.Wang, W.Chen. PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PloS One 2013; 8:e71590; PMID:23977081; http://dx.doi.org/10.1371/journal.pone.0071590
53. H.Laurell, J.S.Iacovoni, A.Abot, D.Svec, J.J.Maoret, J.F.Arnal, M.Kubista. Correction of RT-qPCR data for genomic DNA-derived signals with ValidPrime. Nucleic Acids Res 2012; 40:e51; PMID:22228834; http://dx.doi.org/10.1093/nar/gkr1259
54. S.A.Bustin, V.Benes, J.A.Garson, J.Hellemans, J.Huggett, M.Kubista, R.Mueller, T.Nolan, M.W.Pfaffl, G.L.Shipley et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611-22; PMID:19246619; http://dx.doi.org/10.1373/clinchem.2008.112797